chufangao/CTO huggingface dataset:
Clinical trial NCT03705169: Pharmacokinetics and Safety of SAR441236
Official title: A Phase I, First-in-Human Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants With HIV
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study closed to enrollment and follow-up in May 2023. There had been no enrollment since October 2021, and by 2023, the available study product had reached its expiration date. Enrollment targets in Arm B had not been met.
Enrollment: 52.0 (ACTUAL)
Number of arms: 10.0
Start date: 2019-05-20
Primary completion date: 2022-04-04
Completion date: 2022-04-04
Baseline population: Only participants receiving study treatment were included in the analysis. For analysis, participants receiving placebo (of any dose-volume equivalent) are pooled within arm per the pre-specified analysis plan.
Limitations and caveats: The dosing schedule for many Arm A Cohort 4 participants was interrupted by the COVID-19 pandemic and associated study pause. Enrollment in Arm B was limited. Protocol V3.0 closed the 1 mg/kg cohort and opened the 30 mg/kg cohort. Protocol V4.0 modified the eligibility criteria to boost enrollment but, despite the study remaining open through April 2023, no more participants enrolled. Neither Arm B cohort fully enrolled and the intermediate dose cohorts (3 and 10 mg/kg) did not open.
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie results in the publication, after deidentification.
IPD time frame: Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.
IPD access criteria: * With whom?~  * Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.~* For what types of analyses?~  * To achieve aims in the proposal approved by the AIDS Clinical Trials Group.~* By what mechanism will data be made available?~  * Researchers may submit a request for access to data using the AIDS Clinical Trials Group Data Request form at: https://submit.mis.s-3.net/ Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.
Clinical trial NCT02801448: Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes
Official title: Randomized Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes
Sponsor: Region Skane (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 103.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-09-30
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Plan to share individual participant data: NO
Clinical trial NCT04470622: Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19
Sponsor: Heron Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study was terminated early by Heron, and was not terminated for safety reasons.
Enrollment: 27.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-20
Primary completion date: 2021-04-09
Completion date: 2021-06-03
Baseline population: Safety Population.
Limitations and caveats: Study was terminated early by Heron, and was not terminated for safety reasons. The data reported is only safety data generated from the study.
Plan to share individual participant data: NO
Clinical trial NCT04071626: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure
Official title: The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure
Acronym: EMMED-HF
Sponsor: University Hospitals Cleveland Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of enrollment
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-01
Primary completion date: 2023-01-11
Completion date: 2023-01-11
Plan to share individual participant data: NO
Clinical trial NCT04345471: A Study of MD-120 in Patients With Depression
Official title: A Placebo-controlled Study of MD-120 in Patients With Depression
Sponsor: Mochida Pharmaceutical Company, Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 615.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-05-18
Primary completion date: 2022-07-21
Completion date: 2022-09-14
Plan to share individual participant data: NO
Clinical trial NCT02624518: 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Official title: 68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 122.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-11-16
Primary completion date: 2021-07-21
Completion date: 2022-11-30
Plan to share individual participant data: NO
Clinical trial NCT03557970: JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
Official title: A Phase 2 Open-Label Study of the CSF-1R Inhibitor JNJ-40346527 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Sponsor: OHSU Knight Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Not enough enrollment to determine efficacy
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-05
Primary completion date: 2020-09-28
Completion date: 2020-09-28
Clinical trial NCT02832544: INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority
Official title: INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies
Acronym: INVICTUS-VKA
Sponsor: Population Health Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 4565.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-22
Primary completion date: 2022-08-18
Completion date: 2022-08-18
Plan to share individual participant data: NO
IPD sharing description: cumulative participant data only
Clinical trial NCT04673214: Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment
Official title: Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20
Sponsor: Coordinación de Investigación en Salud, Mexico (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 114.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-16
Primary completion date: 2021-02-25
Completion date: 2021-02-25
Baseline population: Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.
Plan to share individual participant data: NO
IPD sharing description: SHARED VIA EMAIL IF OTHER RESEARCHERS REQUIRE IT
Clinical trial NCT05127811: A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma
Official title: A Phase I Dose Escalation Study of ZN-d5 Monotherapy in Chinese Subjects With Non-Hodgkin Lymphoma
Sponsor: Zentera Therapeutics HK Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 8.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-10-21
Primary completion date: 2023-05-26
Completion date: 2023-05-26
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04006847: Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Official title: Effect of Omega-3 Fatty Acid, Eicosapentaenoic Acid, and Its Metabolites in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase
Sponsor: Milton S. Hershey Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Product complaint
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-14
Primary completion date: 2021-05-21
Completion date: 2021-05-21
Limitations and caveats: Due to the product issues, the trials was halted.
Plan to share individual participant data: NO
Clinical trial NCT03705351: Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
Official title: Safety and Tolerability of Tumor Treating Fields (TTFields) Combined With Chemoradiation in Newly Diagnosed Glioblastoma (Unity)
Sponsor: Providence Health & Services (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Prinicipal Investigator departure from institution
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-02
Primary completion date: 2021-02-24
Completion date: 2022-02-24
Baseline population: Newly diagnosed patients histologically confirmed glioblastoma after maximally safe resection
Limitations and caveats: Early termination leading to small numbers of subjects analyzed
Plan to share individual participant data: NO
Clinical trial NCT05710315: Use of ReliZORB for Feeding Intolerance in Critically Ill Patients
Official title: Single-center, Open-label, Prospective Randomized (Double-Blind) Study on the Use of ReliZORB™ for the Treatment of Feeding Intolerance in Critically Ill Adults With Multi Organ Failure
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: PI initiated study closure. He will be leaving the study site for a new position in the coming months.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-05-01
Primary completion date: 2023-07-30
Completion date: 2024-01-30
Plan to share individual participant data: NO
Clinical trial NCT04158830: Aspirin (ASA) Therapy and Preeclampsia Prevention
Official title: A Pragmatic Randomized Study Comparing 81 mg Aspirin Versus 162 mg Aspirin in the Prevention of Preeclampsia During Pregnancy
Sponsor: University of Tennessee (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: PI is no longer at this University.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-01
Primary completion date: 2021-11-30
Completion date: 2021-11-30
Plan to share individual participant data: NO
Clinical trial NCT03500939: Penumbral Rescue by Normobaric O2 Administration in Patients With Ischemic Stroke and Target Mismatch ProFile
Official title: Penumbral Rescue by Normobaric O=O Administration in Patients With Ischemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial
Acronym: PROOF
Sponsor: University Hospital Tuebingen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Futility
Enrollment: 223.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-01
Primary completion date: 2022-05-16
Completion date: 2022-08-22
Clinical trial NCT02675426: A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
Official title: A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
Acronym: SELECT-NEXT
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 661.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-12-17
Primary completion date: 2017-04-21
Completion date: 2022-03-10
Baseline population: The Full Analysis Set (FAS) includes all randomized participants who received at least one dose of study drug.~The two placebo groups are combined for analysis of results in Period 1.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT02499354: Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)
Official title: Double-blind Comparator of Efficacy of Oral (Ferrous Sulfate) vs. Intravenous Iron (Ferumoxytol) for Treatment of the Restless Legs Syndrome (RLS) Occurring With Iron Deficient Anemia (IDA)
Sponsor: Auerbach Hematology Oncology Associates P C (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-08-31
Primary completion date: 2021-09-28
Completion date: 2022-05-31
Clinical trial NCT05441826: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
Official title: A Phase 2 Study of VB119 in Adult Subjects With Steroid-Sensitive Primary Minimal Change Disease (MCD) or Primary Focal Segmental Glomerulosclerosis (FSGS)
Sponsor: Tenet Medicines (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor change
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-05-03
Primary completion date: 2023-05-03
Completion date: 2023-10-12
Clinical trial NCT05330013: The Effect of Inflammation in Heart Failure
Official title: Pilot Study to Evaluate the Effect of Inflammation in Heart Failure
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: PI left NIH
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-23
Primary completion date: 2022-06-23
Completion date: 2022-06-23
Clinical trial NCT05087771: In Hospital IM Naltrexone: A Pilot Study
Official title: In Hospital Administration of Extended-Release Naltrexone for Alcohol Use Disorder: A Pilot Study of Feasibility and Acceptability
Acronym: IM-NTX
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: no longer randomized, drug being offered to all patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-31
Primary completion date: 2022-12-31
Completion date: 2023-06-30
Plan to share individual participant data: NO
IPD sharing description: This is not part of our study protocol and will not be included as part of the consent for study participation.
Clinical trial NCT04551352: A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Official title: An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1-Targeting CD3 T-Cell Engager, in Participants With Metastatic Melanoma
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-28
Primary completion date: 2022-07-28
Completion date: 2022-07-28
Plan to share individual participant data: NO
Clinical trial NCT05198349: First in Human Study of M1069 in Advanced Solid Tumors
Official title: First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M1069 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors
Sponsor: EMD Serono (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Overarching portfolio-level review of the company's oncology pipeline resulted in early termination of the study. The study was not terminated due to safety.
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-03-02
Primary completion date: 2023-05-09
Completion date: 2023-08-10
Plan to share individual participant data: NO
IPD sharing description: We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://bit.ly/IPD21
Clinical trial NCT03119064: BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
Official title: BrUOG 329: Onivyde (Nanoliposomal Irinotecan) and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: A Phase IB/IIA Brown University Oncology Research Group Study
Acronym: 329
Sponsor: Brown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: lack of response to study therapy
Enrollment: 12.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-11-30
Primary completion date: 2020-04-10
Completion date: 2021-10-08
Plan to share individual participant data: NO
Clinical trial NCT05364099: Suprascapular Nerve Block for Treatment of Shoulder Pain in Individuals With Spinal Cord Injuries
Official title: Suprascapular Nerve Block for Treatment of Shoulder Pain in Individuals With Spinal Cord Injuries
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Unable to feasibly complete study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-11-27
Primary completion date: 2024-01-01
Completion date: 2024-01-01
Plan to share individual participant data: NO
Clinical trial NCT04071366: A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Official title: A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 112.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-07
Primary completion date: 2023-02-23
Completion date: 2023-08-22
Plan to share individual participant data: NO
Clinical trial NCT04998253: Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2
Official title: A Randomized Pilot Clinical Trial of the Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction of Sevoflurane in Patient's Whit ARDS Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2)
Acronym: COVID-19
Sponsor: Unidad Temporal COVID-19 en Centro Citibanamex (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-01
Primary completion date: 2020-11-30
Completion date: 2021-05-15
Plan to share individual participant data: NO
Clinical trial NCT02015923: Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases
Official title: Multicenter Randomized Study in Patients With Colorectal Cancer With Unresectable Metastases. Impact of Resection vs no Resection of the Primary Tumour as a Survival Factor
Acronym: CCRe-IV
Sponsor: Hospital Universitari de Bellvitge (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Difficulties surrounding recruiting patients
Enrollment: 107.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-12-31
Primary completion date: 2019-06-30
Completion date: 2020-02-29
Clinical trial NCT05482672: GetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and Depression
Official title: GetHealthy-OA: A Biopsychosocial Treatment Approach to Improve Pain and Function for Patients With Comorbid Knee Osteoarthritis, Obesity, and Depression
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-04-30
Primary completion date: 2023-04-30
Completion date: 2023-04-30
Plan to share individual participant data: NO
Clinical trial NCT02798068: Steroids and Microcirculation In Cardiac Surgery
Official title: Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1)
Acronym: SICS
Sponsor: Erasme University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-05-31
Primary completion date: 2021-09-30
Completion date: 2021-09-30
Plan to share individual participant data: NO
Clinical trial NCT02762097: Clinical Pregnancy Rate After Removal of Unsuspected Polyps
Official title: Clinical Pregnancy Rate in Women With Unexplained Infertility After Removal of Unsuspected Intrauterine Pathology
Sponsor: Karachi Medical and Dental College (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Study stopped due to similar case control study already completed
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-01-30
Primary completion date: 2020-01-30
Completion date: 2020-01-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02902484: Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
Official title: A Phase 1b and Pharmacodynamic Study of Nintedanib Monotherapy for Advanced Pancreatic Cancer
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to futility and lack of future funding
Enrollment: 14.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-09-07
Primary completion date: 2021-10-26
Completion date: 2021-10-26
Plan to share individual participant data: NO
Clinical trial NCT04108377: Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma
Official title: Phosphodiesterase 4 Inhibitor, Roflumilast, Improves Beta Agonist Responsiveness Compared to Placebo in Low T2 Asthma Patients.
Sponsor: University of California, Davis (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Enrollment stopped secondary to completion of funding
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-21
Primary completion date: 2022-12-11
Completion date: 2023-08-15